News and Events

Home

News and Events

Media Advisories

Updates for media on the latest products, offerings and developments across our business.

Press Releases

��ӰԺ and Elpida Therapeutics Enter Strategic Partnership for Late-Phase AAV Manufacturing

May 13, 2026

Elpida Therapeutics, a non-profit biotechnology company developing gene therapies for ultra-rare diseases, and ��ӰԺ., the leader in enabling the development and supply of better treatments for patients worldwide, today announced a strategic partnership to support late-phase manufacturing of Elpida’s lead program, an AAV9 gene therapy for Spastic Paraplegia Type 50 (SPG50).

Cartherics and ��ӰԺ Expand Commercial License Agreement

Apr 9, 2026

Cartherics Pty Ltd, a biotechnology company developing off‑the‑shelf immune cell therapies for high‑impact women’s diseases, including ovarian cancer and endometriosis, and ��ӰԺ., the leader in enabling the development and supply of better treatments for patients worldwide, today announced an enhanced partnership

��ӰԺ and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases

Mar 11, 2026

GelMEDIX Inc., a biotechnology company developing regenerative therapies to restore vision, and ��ӰԺ., the leader in enabling the development and supply of better treatments for patients worldwide, today announced a global partnership to access ��ӰԺ’s GMP-induced pluripotent stem cells (iPSC) and ��ӰԺ’s cell therapy manufacturing expertise and capabilities to support the development and clinical manufacturing of GelMEDIX’s iPSC-derived cell therapies to treat ocular and retinal diseases.

��ӰԺ and S.Biomedics Announce Partnership to Develop and Manufacture TED‑A9

Feb 18, 2026

��ӰԺ and S.Biomedics today announced a strategic partnership to support the development and manufacturing of TED‑A9, S.Biomedics’ allogeneic pluripotent stem-cell-derived ventral midbrain–specific dopaminergic precursor cell therapy being developed for the treatment of Parkinson’s disease.

SmartCella and ��ӰԺ Sign Nonexclusive License Agreement for GMP iPSCs

Jan 12, 2026

SmartCella Holding AB (“SmartCella”), a global biopharma company developing and manufacturing, cutting-edge cell therapy approaches for difficult-to-treat diseases, and ��ӰԺ., the leader in enabling the development and supply of better treatments for patients worldwide, today announced a nonexclusive license agreement for SmartCella to use ��ӰԺ’s proprietary off-the-shelf GMP compliant induced pluripotent stem cells (iPSCs) for research, development and clinical translation of novel allogeneic stem cell-based regenerative therapies.

��ӰԺ’s SMARTag®ADC Pipeline and New Enhanced Conjugates Offering Featured at 16th World ADC San Diego

Nov 4, 2025

��ӰԺ., a leading global contract development and manufacturing organization, today highlighted new innovations from its SMARTag® antibody-drug conjugate (ADC) technology platform.

��ӰԺ Debuts New Corporate Brand, Elevating Customer Service Excellence by “Championing the Missions that Matter™”

Oct 27, 2025

Relocation reflects a strategic expansion in Florida alongside long-standing manufacturing facility in nearby St. Petersburg.

��ӰԺ Announces Opening of its New Global Corporate Headquarters in Tampa, Florida

Sep 22, 2025

Relocation reflects a strategic expansion in Florida alongside long-standing manufacturing facility in nearby St. Petersburg. New headquarters designed to support innovation, collaboration and growth.

��ӰԺ Announces New Board Appointments

Feb 20, 2025

��ӰԺ., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership.